Literature DB >> 2553044

Effects of chronic antidepressant and benzodiazepine treatment on corticotropin-releasing-factor receptors in rat brain and pituitary.

D E Grigoriadis1, D Pearsall, E B De Souza.   

Abstract

We examined the effects of chronic treatment with antidepressants (imipramine or desipramine) or benzodiazepines (diazepam, alprazolam, or adinazolam) on modulation of corticotropin-releasing-factor (CRF) receptors in discrete areas of rat brain and in anterior pituitary. As previously reported, we found that chronic antidepressant treatment downregulated 5-HT2 serotonin and beta-adrenergic receptors in cerebral cortex. Although there was a trend toward increased CRF binding in brain stem, striatum, cerebellum, hypothalamus, and frontal cerebral cortex following antidepressant treatment, the changes were only statistically significant in brain stem in imipramine-treated rats. In addition, no significant changes were seen in CRF binding in other brain regions including parietal/temporal cerebral cortex, olfactory bulb, hippocampus, and anterior pituitary. Following chronic benzodiazepine treatment CRF receptor binding was significantly decreased in the frontal cerebral cortex and hippocampus; although there was a trend for CRF receptors to be decreased in other brain areas and increased in anterior pituitary, the changes were not statistically significant.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2553044     DOI: 10.1016/0893-133x(89)90007-9

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  9 in total

Review 1.  Benzodiazepines and anterior pituitary function.

Authors:  E Arvat; R Giordano; S Grottoli; E Ghigo
Journal:  J Endocrinol Invest       Date:  2002-09       Impact factor: 4.256

2.  Effects of the combination of metyrapone and oxazepam on cocaine and food self-administration in rats.

Authors:  Nicholas E Goeders; Glenn F Guerin
Journal:  Pharmacol Biochem Behav       Date:  2008-07-19       Impact factor: 3.533

Review 3.  Innovative approaches for the treatment of depression: targeting the HPA axis.

Authors:  Fiona Thomson; Mark Craighead
Journal:  Neurochem Res       Date:  2007-10-25       Impact factor: 3.996

4.  Escitalopram alters gene expression and HPA axis reactivity in rats following chronic overexpression of corticotropin-releasing factor from the central amygdala.

Authors:  Elizabeth I Flandreau; Chase H Bourke; Kerry J Ressler; Wylie W Vale; Charles B Nemeroff; Michael J Owens
Journal:  Psychoneuroendocrinology       Date:  2012-12-23       Impact factor: 4.905

5.  Reduced vasopressin receptors activation mediates the anti-depressant effects of fluoxetine and venlafaxine in bulbectomy model of depression.

Authors:  María Belén Poretti; Rahul S Sawant; Mathias Rask-Andersen; Marta Fiol de Cuneo; Helgi B Schiöth; Mariela F Perez; Valeria Paola Carlini
Journal:  Psychopharmacology (Berl)       Date:  2015-12-23       Impact factor: 4.530

6.  Acute treatment with antidepressant drugs selectively increases the expression of c-fos in the rat brain.

Authors:  C H Beck
Journal:  J Psychiatry Neurosci       Date:  1995-01       Impact factor: 6.186

Review 7.  Genetic Polymorphism of Angiotensin-Converting Enzyme and Chronic Obstructive Pulmonary Disease Risk: An Updated Meta-Analysis.

Authors:  Sang Wook Kang; Su Kang Kim; Joo-Ho Chung; Hee-Jae Jung; Kwan-Il Kim; Jinju Kim; Ju Yeon Ban
Journal:  Biomed Res Int       Date:  2016-10-18       Impact factor: 3.411

8.  Differences in Leukocyte Telomere Length between Coronary Heart Disease and Normal Population: A Multipopulation Meta-Analysis.

Authors:  Xiaofeng Xu; Haochang Hu; Ying Lin; Fangzhong Huang; Huihui Ji; Yin Li; Shaoyi Lin; Xiaomin Chen; Shiwei Duan
Journal:  Biomed Res Int       Date:  2019-05-06       Impact factor: 3.411

9.  Prediction of new drug indications based on clinical data and network modularity.

Authors:  Liang Yu; Xiaoke Ma; Long Zhang; Jing Zhang; Lin Gao
Journal:  Sci Rep       Date:  2016-09-28       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.